Citron's Andrew Left said he is not done with Valeant (VRX) story; Will pass info to main stream media

Valeant Pharma (VRX) Adds to Gains

Beaten down Valeant Pharma (NYSE: VRX) is adding to yesterday's gains in pre-open trade. Shares are up 5.8% to $106.28 after rising 7.15% yesterday. Shares have been under extreme pressure as short sellers point to fraud at the company and regulators point to 'price... More

Bill Ackman's Pershing Square Down 19% YTD (VRX)

Bill Ackman's Pershing Square Holdings, Ltd. released its regular monthly Net Asset Value (NAV) and Performance Report for the month of October 2015. Data showed the fund was down 7.3% during the month and is now down 19% on the year.

Much of the weakness is tied to the hedge fund's oversized... More

Valeant Pharma (VRX) Issues Dear Doctor Letter; Philidor Issues Release - Evercore ISI

Evercore ISI analyst Umer Raffat noted two new developments in the Valeant Pharma (NYSE: VRX) saga. First the company sent a dear doctor letter to dermatologists and separately, Philidor issued a press release.

Raffat highlighted the following from the letter:

Dead Cat Bounce, Or is a Sustainable Relief Rally in Store for Valeant (VRX)?

Citron Research founder Andrew Left's decision to step back from publishing incremental negative research on Valeant (NYSE: VRX) does absolutely nothing to change the fact that there are things we simply don't know about the company's financials, however it does temporarily remove the threat of death by 1000 tweets. This could open the door for analysts who had been supportive of the company... More

Citron's Andrew Left denies he made $150 million short Valeant (VRX)

Citron's Andrew Left denies he made $150 million short Valeant (NYSE: VRX).

Citron's Left stands by story on Valeant (VRX)

Citron's Left stands by story on Valeant (NYSE: VRX)

Citron's Left said "I have nothing with Bill Ackman. This is about Valeant (VRX)"

Citron's Left said "I have nothing with Bill Ackman. This is about Valeant (NYSE: VRX)."

Citron's Left said he was not contacted by the SEC on Valeant Pharma (VRX) over the weekend

Citron's Left said he was not contacted by the SEC on Valeant Pharma (NYSE: VRX) over the weekend.

Valeant Pharma (VRX) story 'taken on a life of its own" - Citron's Left

Valeant Pharma (NYSE: VRX) story 'taken on a life of its own" - Citron's Left

Valeant Pharma (VRX) on Watch Ahead of Citron Left Interview

Bouncing 8% in early trade after Citron Research dialed back on the explosiveness of its report, Valeant Pharma (NYSE: VRX) is on watch ahead of Citron's Andrew Left interview on CNBC at 12PM ET.

Left... More